Meet us in person

Digital health services must be powerful, scalable, and trustworthy. Many organizations face a dilemma: European cloud providers promise legal certainty, while US hyperscalers offer speed, scalability, and advanced analytics capabilities—but also entail legal risks, such as those posed by the US CLOUD Act.

The presentation “Are US hyperscalers evil? – A practical path to cloud sovereignty without runaway effort” by Dr. Roswitha Gostner shows a pragmatic way to cloud sovereignty in healthcare without slowing down innovation or causing costs to skyrocket. Based on experience from the SEMECO research project and the development of productive medical platforms, a hybrid multi-cloud approach is presented:

• Separation of sensitive, patient-identifiable data from analysis and research workloads
• EU controlled keys and data sovereignty as the core of sovereign architectures
  
• Use of hyperscalers where they add value – on de-identified data
  
• Provider-neutral design to preserve freedom of choice and action
  
• Zero-trust principles and confidential computing for end-to-end security

The approach is supplemented by lessons learned from practice, including resilience, certification strategy, and the often underestimated importance of access control versus pure data location.

Interoperability is a key enabler of laboratory digitalization, automation, and AI-driven analyses. This presentation outlines the stages of interoperability based on international definitions and examines how connectivity, data management standards, and digital transformation enable seamless system integration.

Particular emphasis is placed on the interplay between syntactic and semantic interoperability in automated laboratories to ensure consistent data interpretation across workflows involving heterogeneous devices and systems.

Through practical examples, we demonstrate how enhanced interoperability supports efficient data exchange and collaboration, fostering innovation in laboratory environments.

Attendees will gain insights into the strategic relevance of interoperability for automation and AI-driven pharmaceutical R&D.